– First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment – – Approval expands Genentech’s fixed-duration portfolio by ...

AbbVie (ABBV) said Friday that the U.S. FDA has approved a supplemental new drug application for its combination regimen of Venclexta (venetoclax) and acalabrutinib to treat previously untreated ...

The Food and Drug Administration has added another supplement product to an existing warning because it contains toxic yellow ...

AbbVie Inc. (NYSE:ABBV) is one of the best value stocks to buy now. On February 20, the US FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line treatment for adults ...

The state Plant Board on Tuesday held off on updating regulations for the agricultural use of dicamba herbicides in Arkansas this summer.

What Is It, and Why Does It Matter? The FDA has approved a new combination treatment for adults with certain cancers of the blood and lymphatic system. The targeted regimen combines Calquence ...

More than 27,000 units of hair regrowth treatment have been recalled.

Stream2Sea is among few brands with shampoo bars meeting USDA biobased standards, reinforcing transparency, science-backed sustainability, and high performance ...

(RTTNews) - Genentech, a member of the Roche Holding AG (RHHBY), said on Friday that the U.S. Food and Drug Administration has approved the combination of Venclexta plus acalabrutinib for the ...

Ruthless Kindness works with human service partners, such as women’s shelters, district attorneys offices, family justice center… NexGard (or afoxolaner) is a chewable prescription medication for dogs ...

As part of an investigation that dates back to 2023, the FDA has identified over two dozen products featuring the plant.

Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher diseaseParis, March 18, 2026. The US Food and Drug ...